Genetic research spawns Qiagen revolution

Article Abstract:

Qiagen N.V. is one of the fastest-growing and most profitable European biotech firms. Qiagen reported $12.4 million in net income for 1998, up 42% from 1997. Qiagen's 1998 revenues from its kits to isolate and purify DNA were $110 million, up 48% from 1997. Analysts expect 30% average annual sales growth through 2001. The company, founded by Metin Colpan in 1984, is formally based in the Netherlands, but has most of its operations in Dusseldorf, Germany. The US accounts for 54% of Qiagen's revenue, compared to just 12% from Germany.

Comment:

Qiagen N.V. is one of the fastest growing and most profitable European biotech firms

Strategy & planning, Netherlands, Germany, Biological Product (except Diagnostic) Manufacturing, Deoxyribonucleic Acid, Management, Biological products industry, DNA, Qiagen N.V.

---

Swiss drug makers battle referendum on genetic research

Article Abstract:

Switzerland's genetic research industry is threatened by a July 7, 1998, national referendum that seeks to deny patents to genetically-altered creatures and ban the use of those creatures in research. The country's scientists and pharmaceutical giants are opposing the proposals, which they claim will deal a death blow to Switzerland's genetic engineering industry. Some are worried that the referendum could begin a domino effect in the region, including Germany which has an emerging genetic engineering industry.

Comment:

Switz: Genetic research ind is threatened by a referendum that could outlaw use of genetically-altered creatures in research

Government regulation (cont), Switzerland, Article

---

Deode genetics plans units for cancer, pharmacogenomics

Article Abstract:

Icelandic Decode Genetics Inc. announces the development of two new units, one for cancer research and the other for pharmacogenomics, in an effort to diversify.

Research and Testing Services, Cancer R&D, Services development, Iceland, Services, Cancer research, deCODE genetics Inc., DCGS

Similar abstracts:

• Abstracts: Toyota says net rose 14% for year, topping forecasts. Nissan Motor posts a large net loss for latest year. Honda records a 12% decline in net income
• Abstracts: Rich is rich and poor is poor. Something for a refresco. Road sense
• Abstracts: Thirst for overseas stocks grows. Asians snub rally as foreigners pour money into local stocks. 'Frontier' stocks keep investors guessing
• Abstracts: UniCredito board to discuss plans for expansion. Italy tells Mediobanca, SAI to make full bid for Fondiaria. Two banks in North Italy plan merger
• Abstracts: Eatons ad creates high expectations. Mott's markets a no-hassles Caesar

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.